

NeuTec Pharma plc

NeuTec Pharma completes recruitment in phase III trial for MRSA drug, Aurograb[®]

16 June 2006 – Manchester, UK: *NeuTec Pharma plc* (“*NeuTec*”), the biopharmaceutical company targeting drug-resistant, life-threatening infections, announces that Aurograb[®], which targets MRSA, the hospital “superbug”, has completed recruitment in a double-blind placebo-controlled phase III clinical trial. Results of the trial are expected towards the end of 2006 following analysis of the unblinded data.

The study was carried out in a total of 38 centres in six European countries and involved the recruitment of 161 adult hospitalised patients with deep-seated staphylococcal infections. The trial compared the effects of Aurograb[®] in combination with vancomycin versus vancomycin plus placebo in the treatment of MRSA infection.

This trial follows an earlier phase IIb study which was completed in June 2003 and found the drug to be well tolerated and demonstrated a profile that supports likely activity against MRSA in man.

Professor James Burnie, Chief Executive of *NeuTec*, said, “MRSA is a very dangerous life-threatening superbug. With few solutions available on the market today, there is a burning need to provide a powerful drug to combat this dangerous bug.”

-ends-

For further details please contact:

NeuTec Pharma plc

Professor James Burnie, CEO

Andrew King, Finance Director

www.neutecpharma.com

0161 276 8827

07771 867890

Financial Dynamics

Ben Atwell

0207 831 3113

Notes to editors:

NeuTec Pharma plc is a biopharmaceutical company formed in 1997 specialising in the development of genetically recombinant antibodies, or “grabs”, for the treatment of life-threatening infections. In February 2002 the Company’s equity was admitted on the Alternative Investment Market (“AIM”) of the London Stock Exchange.

The development of *NeuTec's* products differs from the traditional approach used by conventional pharmaceutical companies which screen numerous chemical compounds for activity against bacteria and fungi. Many of these compounds will be too toxic for human use. In contrast, *NeuTec* identifies naturally occurring potentially protective antibodies from patients who have recovered from bacterial and fungal infections and then uses these to generate “grabs” to treat these infections. As a result, these “grabs” are likely to be intrinsically safer than antibiotics.

NeuTec's two leading drug candidates are Mycograb®, which targets systemic candidiasis, breast cancer and cryptococcal meningitis, and Aurograb®, which targets *Staphylococcus aureus* including methicillin-resistant *Staphylococcus aureus* (MRSA”).

MRSA, *Methicillin Resistant Staphylococcus aureus* is regarded as the hospital ‘superbug’ by virtue of its ability to spread and cause outbreaks with a high mortality rate of up to 60%. Fatal and non-fatal cases have risen 15-fold in the last decade.